Icahn Enterprises
grail process failures questionable efficacy | Icahn Enterprises
Company
Deck Type
Sector
Industry
Deck date
April 2023
Slide
17 of 37
Related slides by other companies
Erasca
Investor Presentation
November 2023
early clinical data reinforce potential of eras as a backbone to treat patients with cancers including | Erasca
P3 Health Partners
Investor Conference
September 2023
the economic model works improving costs and outcomes contracts with high quality contract with to patients are supported | P3 Health Partners
23andMe
Investor Day
January 2022
human genetics has the potential to double the probability of success in drug development wrong wrong outcomes and translational mitigate | 23andMe
Erasca
Investor Presentation
August 2023
early clinical data reinforce potential of eras as a backbone to treat patients with cancers including | Erasca
Other recent decks by Icahn Enterprises
See all presentations (4 decks)
Activist
May 2022
Activist
November 2018
Activist
April 2018
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io